Przybilla B, Ruëff F
Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität, München, Deutschland.
Wien Med Wochenschr. 1999;149(14-15):421-8.
Hyposensitization (immunotherapy) of hymenoptera venom allergy has been practised for 70 years. About 20 years ago the use of ineffective whole-body extracts was abandoned, as effective therapy with preparations of bee venom and wasp venom became available. The diagnosis of hymenoptera venom allergy is based on history, skin tests and determination of venom specific IgE-antibodies in the serum. Only rarely other tests are needed (histamine or leukotriene release tests, immunoblot, specific IgG antibodies). To achieve a definite diagnosis, all findings have to be considered carefully, as "false positive" and "false negative" results can occur in all test systems. Hyposensitization is indicated in all patients with systemic IgE-mediated immediate type reactions, only in children with exclusive skin symptoms it may not be needed. Contraindications of hyposensitization are to be considered. Allergen preparations for subcutaneous injection are available as aqueous preparations or as aluminium hydroxide-adsorbed depot extracts. Various rush or conventional treatment protocols are used to reach the maintenance dose of usually 100 micrograms venom/four weeks. The most frequent side effects are large local reactions, which are observed in almost all patients. Systemic anaphylactic side effects also occur in up to 40%, in most cases the symptoms are mild. To identify patients who are not protected by the usual maintenance dose, a sting challenge test with a living insect should be performed. By this, about 80 to 100% of the patients are found to be protected from systemic symptoms, and in those still reacting an increased dose of 200 micrograms (or even higher) eventually induces protection. Hyposensitization may be stopped if it lasted at least for 3 to 5 years, if systemic side-effects did not occur and if the patient has tolerated a sting challenge or a field-sting without systemic symptoms. In patients intensely exposed to hymenoptera or in those with an increased risk of severe reactions, longer treatment has to be considered.
膜翅目昆虫毒液过敏的减敏治疗(免疫疗法)已应用了70年。大约20年前,由于有了有效的蜂毒和黄蜂毒液制剂,无效的全身体外提取物的使用被摒弃。膜翅目昆虫毒液过敏的诊断基于病史、皮肤试验以及血清中毒液特异性IgE抗体的测定。仅在极少数情况下需要其他检查(组胺或白三烯释放试验、免疫印迹、特异性IgG抗体)。为了得出明确诊断,必须仔细考虑所有检查结果,因为在所有检测系统中都可能出现“假阳性”和“假阴性”结果。所有全身性IgE介导的速发型反应患者均需进行减敏治疗,仅皮肤症状单一的儿童可能无需进行。减敏治疗的禁忌证也需考虑。皮下注射用变应原制剂有水性制剂或氢氧化铝吸附长效提取物两种。可采用各种快速或传统治疗方案来达到通常为100微克毒液/四周的维持剂量。最常见的副作用是大面积局部反应,几乎所有患者都会出现。全身性过敏副作用发生率也高达40%,大多数情况下症状较轻。为了识别未受常规维持剂量保护的患者,应进行活昆虫叮咬激发试验。通过该试验,约80%至100%的患者被发现可免受全身症状影响,对于仍有反应的患者,增加至200微克(甚至更高)的剂量最终可诱导产生保护作用。如果减敏治疗持续至少3至5年、未出现全身性副作用且患者耐受了叮咬激发试验或野外叮咬且无全身症状,则可停止治疗。对于膜翅目昆虫暴露程度高的患者或严重反应风险增加的患者,需考虑延长治疗时间。